197 related articles for article (PubMed ID: 27378568)
1. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
4. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
[No Abstract] [Full Text] [Related]
9. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
10. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Nijenhuis CM; Huitema AD; Marchetti S; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2016 Oct; 56(10):1307-12. PubMed ID: 26918324
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
13. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
14. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
16. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.
Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Funck-Brentano C; Saiag P
Ann Oncol; 2015 Jul; 26(7):1470-5. PubMed ID: 25899783
[TBL] [Abstract][Full Text] [Related]
17. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
20. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]